Nisa Investment Advisors LLC held its stake in Zimmer Biomet Holdings Inc. (NYSE:ZBH) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 67,319 shares of the company’s stock at the end of the third quarter. Nisa Investment Advisors LLC’s holdings in Zimmer Biomet Holdings were worth $8,753,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Liberty Capital Management Inc. purchased a new stake in Zimmer Biomet Holdings during the third quarter valued at $108,000. Tower Research Capital LLC TRC raised its position in Zimmer Biomet Holdings by 205.3% in the second quarter. Tower Research Capital LLC TRC now owns 916 shares of the company’s stock valued at $110,000 after buying an additional 616 shares during the period. Global X Management Co. LLC raised its position in Zimmer Biomet Holdings by 238.4% in the second quarter. Global X Management Co. LLC now owns 1,032 shares of the company’s stock valued at $124,000 after buying an additional 727 shares during the period. Enterprise Financial Services Corp raised its position in Zimmer Biomet Holdings by 173.9% in the second quarter. Enterprise Financial Services Corp now owns 1,260 shares of the company’s stock valued at $151,000 after buying an additional 800 shares during the period. Finally, IFP Advisors Inc raised its position in Zimmer Biomet Holdings by 0.5% in the second quarter. IFP Advisors Inc now owns 1,507 shares of the company’s stock valued at $181,000 after buying an additional 8 shares during the period. Hedge funds and other institutional investors own 85.05% of the company’s stock.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded up 1.40% during mid-day trading on Tuesday, hitting $103.41. The company had a trading volume of 1,436,370 shares. The firm has a 50-day moving average price of $112.33 and a 200 day moving average price of $121.63. Zimmer Biomet Holdings Inc. has a 12 month low of $88.27 and a 12 month high of $133.21. The firm has a market capitalization of $20.71 billion, a P/E ratio of 57.90 and a beta of 1.28.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings results on Monday, October 31st. The company reported $1.79 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.79. The firm had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $950.20 million. Zimmer Biomet Holdings had a return on equity of 16.48% and a net margin of 3.46%. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.64 EPS. On average, equities research analysts forecast that Zimmer Biomet Holdings Inc. will post $7.92 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Zimmer Biomet Holdings Inc. (ZBH) Position Maintained by Nisa Investment Advisors LLC” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US & international trademark and copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/29/zimmer-biomet-holdings-inc-zbh-position-maintained-by-nisa-investment-advisors-llc.html.

ZBH has been the topic of several analyst reports. Northcoast Research lowered Zimmer Biomet Holdings from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 8th. Needham & Company LLC upgraded Zimmer Biomet Holdings from a “buy” rating to a “strong-buy” rating and cut their target price for the company from $150.00 to $148.00 in a research note on Tuesday, November 1st. Jefferies Group reiterated a “buy” rating and issued a $150.00 target price on shares of Zimmer Biomet Holdings in a research note on Monday, August 8th. Argus reiterated a “buy” rating and issued a $140.00 target price on shares of Zimmer Biomet Holdings in a research note on Thursday, September 22nd. Finally, Royal Bank Of Canada cut their target price on Zimmer Biomet Holdings from $143.00 to $130.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 1st. Four analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $131.15.

In related news, insider Daniel E. Williamson sold 2,716 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $129.96, for a total transaction of $352,971.36. Following the transaction, the insider now owns 2,000 shares in the company, valued at approximately $259,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.22% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.